CAY10773 is a derivative of the ferroptosis inducer sorafenib .1 It selectively inhibits proliferation of BEL-7402, MGC803, and T24 bladder cancer cells (IC50s = 5.77, 5.21 and 3.97 µM, respectively) over non-cancerous HCV-29 cells (IC50 = 23.19 µM). CAY10773 induces apoptosis in T24 cells when used at concentrations ranging from 2 to 6 µM but induces ferroptosis at concentrations greater than or equal to 6 µM with 10 hour or longer incubation times. It increases the production of reactive oxygen species (ROS) and decreases the mitochondrial membrane potential in T24 cells. CAY10773 (≥6 µM) also induces autophagy with incubation times longer than eight hours.
1.Chen, J.-N., Li, T., Cheng, L., et al.Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivativesEur. J. Med. Chem.205112661(2020)